Shionogi and Medicines Patent Pool Partner To Bring COVID-19 Anti-Viral To 117 Countries
Shionogi Follows Pfizer And Merck In Striking LMIC Anti-viral Agreement With MPP
Executive Summary
A license agreement between Shionogi and the Medicines Patent Pool aims to widen access to Shionogi’s oral COVID-19 anti-viral ensitrelvir in low to middle-income countries. The investigational drug reduced Omicron-related symptoms in a recent Phase III trial.
You may also be interested in...
Medicines Patent Pool Facilitates Deals With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
MPP Facilitates Agreements With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
Asia Deal Watch: Astellas Invests In Taysha, Gets Rights To Two AAV Gene Therapies
Plus deals involving Takeda/Zedira/Dr. Falk, Lupin/Sunovion, Eucure/Syncromune, Hetero/Johnson & Johnson, Nitto Denko/Omega, Harbour BioMed/CSPC and Pregene/Bone Therapeutics.